Contrasting Immunovant (NASDAQ:IMVT) & Genfit (NASDAQ:GNFT)

Immunovant (NASDAQ:IMVT) and Genfit (NASDAQ:GNFT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Immunovant and Genfit, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	0	1	10	0	2.91
Genfit	0	0	1	0	3.00

Immunovant currently has a consensus target price of $47.00, indicating a potential upside of 100.85%. Genfit has a consensus target price of $13.00, indicating a potential upside of 258.62%. Given Genfit’s stronger consensus rating and higher probable upside, analysts plainly believe Genfit is more favorable than Immunovant.

Insider and Institutional Ownership

47.1% of Immunovant shares are held by institutional investors. Comparatively, 2.2% of Genfit shares are held by institutional investors. 5.9% of Immunovant shares are held by insiders. Comparatively, 4.2% of Genfit shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Immunovant has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Immunovant and Genfit’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-56.40%	-52.03%
Genfit	N/A	N/A	N/A

Valuation & Earnings

This table compares Immunovant and Genfit”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$259.34 million	($2.22)	-10.54
Genfit	$41.31 million	4.39	-$31.27 million	N/A	N/A

Genfit has higher revenue and earnings than Immunovant.

Summary

Genfit beats Immunovant on 7 of the 10 factors compared between the two stocks.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.